VPC-14449

• Description:

  VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer[1][2].

• UNSPSC:

  12352005

• Target:

  Androgen Receptor

• Type:

  Reference compound

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/vpc-14449.html

• Concentration:

  10mM

• Purity:

  99.51

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  BrC1=CN(C2=CSC(N3CCOCC3)=N2)C(Br)=N1

• Molecular Formula:

  C10H10Br2N4OS

• Molecular Weight:

  394.09

• References & Citations:

  [1]Dalal K, et, al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014 Sep 19;289 (38) :26417-26429.|[2]Dalal K, et, al. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. Mol Cancer Ther. 2017 Oct;16 (10) :2281-2291.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1621375-32-3]